Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: Results of a prospective trial

Journal of Clinical Oncology

Volumn 21, Issue 3, 2003, Pages 428-432

  Downey, Robert J ^a   Akhurst, Tim ^a   Ilson, David ^a   Ginsberg, Robert ^a   Bains, Manjit S ^a   Gonen, Mithat ^a   Koong, Heng ^a   Gollub, Marc ^a   Minsky, Bruce D ^a   Zakowski, Maureen ^a   Turnbull, Alan ^a   Larson, Steven M ^a   Rusch, Valerie ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; METASTASIS; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE COURSE; ESOPHAGUS TUMOR; MIDDLE AGED; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0037317691     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.04.013     Document Type: Article

References (24)

1. King MR, Pairolero PC, Trastek VF, et al: Ivor Lewis esophagectomy for carcinoma of the esophagus: Early and late functional results. Ann Thorac Surg 44:119-122, 1987
2. Forastiere AA, Orringer MB, Perez-Tamayo C, et al: Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of esophagus: A final report. J Clin Oncol 11:1118-1123, 1993
3. Walsh TN, Noonan N, Hollywood D, et al: A comparison of multimodality therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335:462-467, 1996
4. Urba SG, Orringer MB, Turrisi A, et al: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19:305-313, 2001
5. Bosset JF, Gignoux M, Triboulet JP, et al: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl Med 337:161-167, 1997
6. Jones DR, Parker LA Jr., Detterbeck FC, et al: Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 85:1026-1032, 1999
7. Flamen P, Lerut A, Van Cutsem E, et al: Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 18:3202-3210, 2000
8. Block MI, Patterson GA, Sundaresan RS, et al: Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 64:770-777, 1997
9. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
10. Hiraki Y, Rosen OM, Birnbaum MJ: Growth factors rapidly induce expression of the glucose transporter gene. J Biol Chem 263:13655-13662, 1988
11. 18fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 60:1348-1352, 1995
12. Mineura K, Yasuda T, Kowada M, et al: Positron emission tomographic evaluation of radiochemotherapeutic effect on regional cerebral hemocirculation and metabolism in patients with gliomas. J Neurooncol 5:277-285, 1987
13. Ogawa T, Uemura K, Shishido F, et al: Changes of cerebral blood flow, and oxygen and glucose metabolism following radiochemotherapy of gliomas: A PET study. J Comput Assist Tomogr 12:290-297, 1988
14. Friedman HS, Schold SC Jr., Djang WT, et al: Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor. Neurology 39:62-66, 1989
15. Wahl RL, Zasadny K, Helvie M, et al: Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 11:2101-2111, 1993
16. 18F)fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18:1689-1695, 2000
17. Jansson T, Westlin JE, Ahlstrom H, et al: Positron emission tomography studies in patients locally advanced and/or metastatic breast cancer: A method for early therapy evaluation? J Clin Oncol 13:1470-1477, 1995
18. Findlay M, Young H, Cunnignham D, et al: Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil. J Clin Oncol 14:700-708, 1996
19. Berlangieri SU, Brizel DM, Sher RL, et al: Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy. Head Neck 16:340-346, 1994
20. Romer W, Hanauske AR, Ziegler S, et al: Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood 91:4464-4471, 1998
21. 18F-Fluorodeoxyglucose (FDG-PET) to predict the pathologic response and survival of esophageal cancer after preoperative chemoradiation therapy (CRT). Thirty-seventh Annual Meeting of the American Society of Clinical Oncology, San Francisco, California, May 12-15,2001 (abstr 504)
22. Brucher BL, Weber W, Bauer M, et al: Neoadjuvant therapy of esophageal squamous cell carcinoma; response evaluation by positron tomography. Ann Surg 233:300-309, 2001
23. Weber WA, Ott K, Becker K, et al: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058-3065, 2001
24. 18Fluorodeoxyglucose positron emission tomography. AJR 168:417-424, 1997